Ileocolonic-Targeted JAK Inhibitor: A Safer and More Effective Treatment for Inflammatory Bowel Disease

Janus kinase (JAK) inhibitors, such as tofacitinib (Xeljanz) and filgotinib (Jyseleca), have been approved for treatment of ulcerative colitis with several other JAK inhibitors in late-stage clinical trials for inflammatory bowel disease (IBD). Despite their impressive efficacy, the risk of adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Vipul, House, Aileen, Matiz, Silvia, McCoubrey, Laura E., Bettano, Kimberly A., Bhave, Leena, Wang, Meiyao, Fan, Peter, Zhou, Siqun, Woodhouse, Janice D., Poimenidou, Eirini, Dou, Liu, Basit, Abdul W., Moy, Lily Y., Saklatvala, Robert, Hegde, Laxminarayan G., Yu, Hongshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698010/
https://www.ncbi.nlm.nih.gov/pubmed/36365202
http://dx.doi.org/10.3390/pharmaceutics14112385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698010/
https://www.ncbi.nlm.nih.gov/pubmed/36365202
http://dx.doi.org/10.3390/pharmaceutics14112385

Ejemplares similares